These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21300830)

  • 21. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
    Zhang Z; Patel YT; Fiedler-Kelly J; Feng HP; Bruno CJ; Gao W
    J Clin Pharmacol; 2021 Feb; 61(2):254-268. PubMed ID: 32949031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Saux MC; Gordien JB; Allaouchiche B
    Intensive Care Med; 2006 Dec; 32(12):2059-62. PubMed ID: 17039351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
    Lodise TP; Kinzig-Schippers M; Drusano GL; Loos U; Vogel F; Bulitta J; Hinder M; Sörgel F
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1945-51. PubMed ID: 17485507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients.
    Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2015 May; 45(5):512-8. PubMed ID: 25726443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individual meropenem epithelial lining fluid and plasma PK/PD target attainment.
    Rohani R; Yarnold PR; Scheetz MH; Neely MN; Kang M; Donnelly HK; Dedicatoria K; Nozick SH; Medernach RL; Hauser AR; Ozer EA; Diaz E; Misharin AV; Wunderink RG; Rhodes NJ
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0072723. PubMed ID: 37975660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
    Crandon JL; Luyt CE; Aubry A; Chastre J; Nicolau DP
    J Antimicrob Chemother; 2016 Sep; 71(9):2534-7. PubMed ID: 27272723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa.
    Yamada K; Yamamoto Y; Yanagihara K; Araki N; Harada Y; Morinaga Y; Izumikawa K; Kakeya H; Hasegawa H; Kohno S; Kamihira S
    J Infect Chemother; 2012 Aug; 18(4):472-8. PubMed ID: 22215228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions.
    Layios N; Visée C; Mistretta V; Denooz R; Maes N; Descy J; Frippiat F; Marchand S; Grégoire N
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205221. PubMed ID: 35099273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.
    Wenzler E; Gotfried MH; Loutit JS; Durso S; Griffith DC; Dudley MN; Rodvold KA
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7232-9. PubMed ID: 26349830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
    Oshima K; Nakamura S; Iwanaga N; Takemoto K; Miyazaki T; Yanagihara K; Miyazaki Y; Mukae H; Kohno S; Izumikawa K
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
    Rubino CM; Ma L; Bhavnani SM; Korth-Bradley J; Speth J; Ellis-Grosse E; Rodvold KR; Ambrose PG; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4085-9. PubMed ID: 17846139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
    Nicasio AM; Eagye KJ; Nicolau DP; Shore E; Palter M; Pepe J; Kuti JL
    J Crit Care; 2010 Mar; 25(1):69-77. PubMed ID: 19427167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue.
    Paal M; Scharf C; Denninger AK; Ilia L; Kloft C; Kneidinger N; Liebchen U; Michel S; Schneider C; Schröpf S; Schuster C; Vogeser M; Weinelt F; Zander J; Zoller M; Schroeder I
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0156421. PubMed ID: 34570645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Tait JR; Wallis SC; Peleg AY; Roberts JA; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens.
    Oesterreicher Z; Minichmayr I; Sauermann R; Marhofer D; Lackner E; Jäger W; Maier-Salamon A; Schwameis R; Kloft C; Zeitlinger M
    Eur J Clin Pharmacol; 2017 Dec; 73(12):1609-1613. PubMed ID: 28920154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.
    Rodvold KA; George JM; Yoo L
    Clin Pharmacokinet; 2011 Oct; 50(10):637-64. PubMed ID: 21895037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.